NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

Events
Written By Stine Krag Brunvold

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine

  • ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens muscle fiber excitability and is involved in regulating muscle fiber excitability during exercise

  • Clinical and preclinical data supports the notion that ClC-1 inhibition is a novel and highly translational therapeutic approach to improve symptoms in myasthenia gravis and, potentially, other diseases with compromised neuromuscular transmission

  • NMD670, a skeletal muscle targeted ClC-1 inhibitor, is in clinical development for the treatment of patients with generalized myasthenia gravis, spinal muscular atrophy, and Charcot-Marie- Tooth disease

Stine Krag Brunvold
Previous

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
Next

NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine